Navigation Links
Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial
Date:10/11/2007

REDWOOD CITY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that, as part of a planned interim analysis, it would stop enrollment in a Phase 2 clinical trial evaluating the efficacy and safety of glufosfamide in patients with recurrent, sensitive small cell lung cancer.

The clinical trial utilized a two stage design to ensure there would be an adequate response rate to justify complete enrollment. Tumor response was evaluated at baseline and every six weeks using the Response Evaluation Criteria In Solid Tumors (RECIST). The first stage enrolled 21 patients as planned, but only one confirmed partial response was observed. If three or more responses were observed, an additional 29 patients would have been enrolled. Patients currently enrolled in the clinical trial will be given the option to continue in the trial.

"We are disappointed in the study results. While we recognize that response is not a perfect surrogate for survival, the low response rate indicates that glufosfamide is not sufficiently effective as a single agent for patients with small cell lung cancer. We had hoped to develop a better treatment option for patients with this disease, for whom the quality of life and treatment outcomes need improvement," said Barry Selick, Ph.D., chief executive officer of Threshold. "We want to thank the investigators, patients and their families for their participation in the study."

Phase 2 Clinical Trial Design

Approximately 50 patients with extensive recurrent sensitive small cell lung cancer, who had progressed at least 60 days after completing chemotherapy, were planned to enroll in the Phase 2, open-label, clinical trial at various s
'/>"/>

SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Threshold Pharmaceuticals Announces Multiple Presentations on Oncology Pipeline at the 2007 American Association for Cancer Research (AACR) Annual Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
(Date:1/23/2015)... Jan. 23, 2015  Now available for sale, The Armor1 ... that prevents ankle sprains by cushioning the ankle from ... securely around the outside of any shoe type and ... while still offering protection against sprains. With customers in ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin ... a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities ... update for shareholders detailing why a "YES" vote to increase ... Shareholders, As we reflect upon the 2014 fiscal ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Dec. 16, 2011   Radiotherapy Clinics of Georgia has ... by the physicians of Radiotherapy Clinics of Georgia in January.  ... prostate cancer and treatment options. All Prostate Cancer ... begin with a light dinner at 5 p.m. followed by ...
... 22 bipartisan House Members yesterday wrote to the Centers ... to stop their prepayment review project that could limit ... The lawmakers, who included Rep. Bill Flores (R-TX) and ... access to mobility equipment for Medicare patients and lack ...
Cached Medicine Technology:Radiotherapy Clinics of Georgia Present Prostate Cancer Lecture Series 2Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries 2Bipartisan Group of 22 House Members ask CMS to Stop Prepayment Review Project that would Jeopardize Care for Medicare Beneficiaries 3
(Date:1/23/2015)... 23, 2015 Hastings and Hastings, a law ... a record number of legal representation client review requests for ... been a steady rise in the number of slip and ... home throughout the Valley. With that said, a large number ... by an experienced law firm. Hastings and Hastings is a ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... vitamin D receptors on cancer cells has prompted encouraging ... in men with prostate cancer that has become resistant ... II(a) clinical trial will be presented at the 22nd ... in Berlin today (Thursday). The trial found that when ...
... (New York, NY November 2, 2010) Uniting Against ... Award for Lung Cancer Research." This year,s recipient ... Pathology and Laboratory Medicine and Director, Translational Bioinformatics Program, ... annual Hope Now Award is intended for the research ...
... tracking the fate of a group of immature cells ... Johns Hopkins researchers discovered in mice that these cells ... Gehrig,s disease. A study reported November 17 online ... and expand rapidly during early life, eventually morphing into ...
... , WEDNESDAY, Nov. 17 (HealthDay News) -- Veterans suffering ... at higher risk for heart disease. For the ... (hardening of the arteries), as measured by levels of ... "is emerging as a significant risk factor," said Dr. ...
... Nicholas Kristof declared in his New York Times column what ... but also "women, women, and women." Women are generally thought ... he speculated that the banks could balance out risky men ... influence how women make financial decisions, making them more wary ...
... , WEDNESDAY, Nov. 17 (HealthDay News) -- The ... caffeinated alcoholic beverages that their products are illegal. In ... added to the malt beverages is an "unsafe food additive," ... products. "FDA does not find support for the claim ...
Cached Medicine News:Health News:New drug targets vitamin D receptors in hormone resistant prostate cancers 2Health News:New drug targets vitamin D receptors in hormone resistant prostate cancers 3Health News:Boston University researcher lauded for leading-edge lung cancer research efforts 2Health News:Mysterious cells may play role in ALS 2Health News:Veterans With PTSD May Be at Higher Risk for Heart Disease 2Health News:Veterans With PTSD May Be at Higher Risk for Heart Disease 3Health News:Being faced with gender stereotypes makes women less likely to take financial risks 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 3
McIntyre-Binkhorst, length 18 mm....
McIntyre-Binkhorst Cannula have a smooth blunt tip end opening....
Army/Navy retractor (set of 2)....
Jaffe wire lid retractor, large pair....
Medicine Products: